Holen Sie sich die Stockscreener-App
1.43
2.14%
0.03
Schlusskurs vom Vortag:
$1.40
Offen:
$1.41
24-Stunden-Volumen:
99,815
Relative Volume:
0.54
Marktkapitalisierung:
$43.36M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.24M
KGV:
-1.7066
EPS:
-0.8379
Netto-Cashflow:
$-22.47M
1W Leistung:
-37.83%
1M Leistung:
-49.82%
6M Leistung:
-59.94%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.41
$1.44
1-Wochen-Bereich:
$1.37
$2.35
52-Wochen-Spanne:
$1.37
$17.65
Skye Bioscience Inc Stock (SKYE) Company Profile
Firmenname
Skye Bioscience Inc
Sektor
Branche
Telefon
(858) 410-0266
Adresse
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Vergleichen Sie SKYE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1826 | 380.07M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.61 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.80 | 161.48M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
10.81 | 123.51M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.175 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-09-30 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-09 | Eingeleitet | Craig Hallum | Buy |
| 2024-05-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Skye Bioscience Inc Aktie (SKYE) Neueste Nachrichten
Charles Schwab Investment Management Inc. Has $176,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Charles Schwab Investment Management Inc. Grows Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
10,142 Shares in Skye Bioscience, Inc. (NASDAQ:SKYE) Acquired by Virtu Financial LLC - Defense World
Virtu Financial LLC Invests $29,000 in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $18.00 Average Price Target from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Skye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call Transcript - MSN
Skye Bioscience (NASDAQ:SKYE) Receives Outperform Rating from William Blair - MarketBeat
Skye Bioscience promotes Tu Diep to COO post - The Pharma Letter
Craig Hallum Issues Pessimistic Forecast for Skye Bioscience (NASDAQ:SKYE) Stock Price - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Announces Quarterly Earnings Results - MarketBeat
Skye Bioscience’s SWOT analysis: novel obesity drug stock faces pivotal year - Investing.com Canada
Skye Bioscience’s (SKYE) “Outperform” Rating Reiterated at William Blair - Defense World
Skye Bioscience’s SWOT analysis: novel obesity drug stock faces pivotal year By Investing.com - Investing.com South Africa
SKYE Stock Price and Chart — NASDAQ:SKYE - TradingView
Skye Bioscience’s Positive Earnings Call Highlights Nimacimab Progress - TipRanks
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Skye Bioscience (SKYE) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Citizens JMP reiterates Skye Bioscience at market outperform By Investing.com - Investing.com Canada
Citizens JMP reiterates Skye Bioscience at market outperform - Investing.com India
Skye Bioscience (NASDAQ:SKYE) Shares Down 31% – Time to Sell? - Defense World
Skye Bioscience (NASDAQ:SKYE) Stock Price Down 31% – Time to Sell? - Defense World
Skye Bioscience Reports 2024 Financial Results and Trial Progress - TipRanks
Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period - MSN
Earnings call transcript: Skye Bioscience Q4 2024 highlights financials, product progress - Investing.com
Skye Bioscience Inc. (SKYE) reports earnings - Quartz
Skye Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Skye Bioscience Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Business Update - Marketscreener.com
Skye Bioscience, Inc. SEC 10-K Report - TradingView
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Skye's Obesity Drug Trial Hits Major Milestone with Strong Financial Backing - StockTitan
Skye Bioscience Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
SKYE BIOSCIENCE Earnings Preview: Recent $SKYE Insider Trading, Hedge Fund Activity, and More - Nasdaq
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025 - The Manila Times
Skye Bioscience to Host Conference Call on March 20, 2025, to Discuss Q4 and Full-Year 2024 Financial Results - Nasdaq
Skye Bioscience Q4 Earnings: Obesity Treatment Pioneer Reveals 2024 Financial Performance - StockTitan
Brokerages Set Skye Bioscience, Inc. (NASDAQ:SKYE) Price Target at $18.67 - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Rating of "Buy" by Analysts - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Trading Down 2%Should You Sell? - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Coverage Initiated at William Blair - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Research Coverage Started at William Blair - Defense World
Finanzdaten der Skye Bioscience Inc-Aktie (SKYE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):